August 16, 2022

The August 2022 ‘News from ECOG-ACRIN’ blog is now available

June 22, 2022

FDA approves dabrafenib plus trametinib for BRAF V600E-mutated tumors based on data from NCI-MATCH

June 1, 2022

Precision medicine clinical trials: A conversation between Peter Oโ€™Dwyer and Lale Kostakoglu

May 27, 2022

Press Release: ECOG-ACRIN research highlights at ASCO 2022

May 17, 2022

Media Advisory: ECOG-ACRIN data at ASCO will showcase the Groupโ€™s robust research portfolio

April 11, 2022

As NCI-MATCH winds down, cancer research community takes stock of lessons learned

March 17, 2022

NCI-MATCH umbrella trial adds arm for LAG-3 expressing, mismatch repair deficient cancers

March 16, 2022

Press Release: ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

March 1, 2022

FDA notes the NCI-MATCH trial in its release of new guidance on master protocols and expansion cohorts

ECOG-ACRIN Cancer Research Group